MANAGEMENT OF CARDIORENAL SYNDROME: POTENTIALS FOR USE OF ANGIOTENSIN II RECEPTOR BLOCKERS


如何引用文章

全文:

详细

The article discusses the potentials for use of angiotensin II receptor blockers (ARB) in the treatment of cardiorenal syndrome, including in type 2 diabetes mellitus (DM2). The article presents the results of studies showing that these drugs (in particular, olmesartan) can claim the role of independent strategy of management of cardiorenal syndrome, including its prognostically unfavorable variants, such as type 2 diabetes mellitus, preventing the appearance of microalbuminuria. In this regard, the advisability of early use of ARB can be considered in the presence of risk factors for cardiorenal syndrome (arterial hypertension, type 2 diabetes mellitus, metabolic syndrome). Ability to prevent the key manifestations of cardiorenal syndrome, in particular, microalbuminuria, defines the main approaches to increasing long-term renal and cardiovascular prognosis in patients.

参考

  1. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний // Вестник РАМН 2003. № 11. С. 50-5.
  2. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии // Нефрология 2005. Т. 9. № 3. С. 7-15.
  3. Чазова И.Е., Мычка В.Б. Метаболический синдром // Кардиоваскулярная терапия и профилактика 2003. № 3. С. 32-8.
  4. Шестакова М.В., Ярек-Мартынова И.Р., Иванишина Н.С. Кардиоренальная патология при сахарном диабете 1 типа: механизмы развития и возможности медикаментозной коррекции // Тер. архив 2005. № 6. С. 40-6.
  5. Ronco C, McCullough P, Anker S.D, et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11.
  6. De Jong PE, Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004;66:2109-18.
  7. Ochodnicky P, Henning RH, van Dokkum RP, et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc Pharmacol 2006;47(2):151-62.
  8. Tsakiris A, Doumas M, Lagatouras D, et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology 2006;57(3):313-20.
  9. Metclaf P, Baker J, Scott A, et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin Chem 1992;38:1802-18.
  10. Brown B, Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 2005;18:127-33.
  11. De Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004;66:2109-18.
  12. Ochodnicky P, Henning RH, van Dokkum RP, et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc Pharmacol 2006;47(2):151-62.
  13. Tofe Povedano S, Garcia De La Villa B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich) 2009;11(8):426-31.
  14. Ikeda H, Hamamoto Y, Honjo S, et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009;83(1):117-18.
  15. Ideura H, Hiromura K, Hiramatsu N, et al. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol 2007;293(4):1214-21.
  16. Mima A, Matsubara T, Arai H, et al. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Invest 2006;86(9):927-39.
  17. Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010;28(11):2289-98.
  18. Haller H, Ito S, Izzo JL, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
  19. Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
  20. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
  21. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003;14:641-47.
  22. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151:1-10.
  23. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-40.
  24. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20.
  25. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010;53(1):49-57.
  26. Januszewicz A, Ritz E, Viberti G, et al. Office and ambulatory pulse pressure association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). J Hum Hypertens 2010, Dec 9 [Epub ahead of print].

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##